ES2532089T3 - GH e IGF-1 para el tratamiento de trastornos del crecimiento - Google Patents

GH e IGF-1 para el tratamiento de trastornos del crecimiento Download PDF

Info

Publication number
ES2532089T3
ES2532089T3 ES06784529.7T ES06784529T ES2532089T3 ES 2532089 T3 ES2532089 T3 ES 2532089T3 ES 06784529 T ES06784529 T ES 06784529T ES 2532089 T3 ES2532089 T3 ES 2532089T3
Authority
ES
Spain
Prior art keywords
igf
subject
idb
growth
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06784529.7T
Other languages
English (en)
Spanish (es)
Inventor
Ross G. Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Biopharmaceuticals Inc
Original Assignee
Ipsen Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharmaceuticals Inc filed Critical Ipsen Biopharmaceuticals Inc
Application granted granted Critical
Publication of ES2532089T3 publication Critical patent/ES2532089T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES06784529.7T 2005-06-02 2006-06-01 GH e IGF-1 para el tratamiento de trastornos del crecimiento Expired - Lifetime ES2532089T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68761705P 2005-06-02 2005-06-02
US687617P 2005-06-02
PCT/US2006/021282 WO2006130769A2 (en) 2005-06-02 2006-06-01 Methods for treatment of growth disorders

Publications (1)

Publication Number Publication Date
ES2532089T3 true ES2532089T3 (es) 2015-03-24

Family

ID=37482318

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06784529.7T Expired - Lifetime ES2532089T3 (es) 2005-06-02 2006-06-01 GH e IGF-1 para el tratamiento de trastornos del crecimiento

Country Status (5)

Country Link
US (2) US8158582B2 (enExample)
EP (1) EP1901770B1 (enExample)
JP (2) JP2008545752A (enExample)
ES (1) ES2532089T3 (enExample)
WO (1) WO2006130769A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0812768A2 (pt) 2007-06-08 2014-12-02 Massachusetts Inst Technology Igf para o tratamento de síndrome de rett e transtornos sinápticos.
UA103104C2 (ru) 2009-07-22 2013-09-10 Ипсен Фарма С.А.С. Аналоги инсулиноподобного фактора роста-1 (igf-1), содержащие аминокислотную замену в положении 59
RU2558821C2 (ru) * 2009-11-17 2015-08-10 Ипсен Фарма С.А.С. ЛЕКАРСТВЕННАЯ ФОРМА ДЛЯ КОМБИНАЦИИ hGH И rhIGF-1
JP6382187B2 (ja) * 2012-06-21 2018-08-29 フォスフォレックス，インコーポレーテッド インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
US20170368149A1 (en) * 2014-12-16 2017-12-28 Puretein Bioscience Llc. Methods for increasing serum igf-1 in an animal
PL3672622T3 (pl) * 2017-08-24 2024-04-02 Genzyme Corporation Rekombinowana ludzka kwaśna sfingomielinaza do zastosowania w leczeniu nieprawidłowych stanów kości u pacjentów z niedoborem kwaśnej sfingomielinazy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374620A (en) 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
SE9002731D0 (sv) 1990-08-24 1990-08-24 Kabivitrum Ab Product comprising growth factor
TW267102B (enExample) 1992-03-13 1996-01-01 Ciba Geigy
IL106546A0 (en) 1993-08-01 1993-12-08 Zvi Rozenberg Apparatus for a bicycle and a two wheel vehicle
US5646113A (en) * 1994-04-07 1997-07-08 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5824642A (en) 1994-04-07 1998-10-20 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5741776A (en) 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
DK2274978T3 (en) 2003-09-12 2015-06-15 Ipsen Biopharmaceuticals Inc Methods of treating an insulin-like growth factor-I (IGF-I) deficiency
RU2558821C2 (ru) 2009-11-17 2015-08-10 Ипсен Фарма С.А.С. ЛЕКАРСТВЕННАЯ ФОРМА ДЛЯ КОМБИНАЦИИ hGH И rhIGF-1

Also Published As

Publication number Publication date
WO2006130769A2 (en) 2006-12-07
US20100137200A1 (en) 2010-06-03
EP1901770B1 (en) 2014-12-24
JP2008545752A (ja) 2008-12-18
US20120232009A1 (en) 2012-09-13
WO2006130769A9 (en) 2007-01-18
JP2014129405A (ja) 2014-07-10
US8440616B2 (en) 2013-05-14
WO2006130769A3 (en) 2009-04-16
US8158582B2 (en) 2012-04-17
EP1901770A4 (en) 2010-11-03
EP1901770A2 (en) 2008-03-26

Similar Documents

Publication Publication Date Title
Hummer et al. Hyperprolactinaemia and antipsychotic therapy in schizophrenia
Farr et al. Leptin applications in 2015: what have we learned about leptin and obesity?
Mahan et al. Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement
US8946152B2 (en) Method of treating parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
ES2330671T3 (es) Amilina y agonistas de amilina para el tratamiento de enfermedades y trastornos psiquiatricos.
US20100004166A1 (en) Endothelin and Endothelin Receptor Agonists in the Treatment of Metabolic Diseases
Page-Wilson et al. Hypothalamic obesity in patients with craniopharyngioma: treatment approaches and the emerging role of gastric bypass surgery
BRPI0712147A2 (pt) polipeptìdeos estabilizados do fator do crescimento insulina-like
Sartorio et al. Adults with childhood‐onset growth hormone deficiency: effects fo growth harmone treatment on cardiac structure
Fine Stimulating growth in uremic children
CN105072909A (zh) 应用控制食欲不振的化合物的组合物和方法
US8440616B2 (en) Methods for treatment of insulin-like growth factor-1 deficiency
JP7120718B2 (ja) 体重増加用化合物の長期使用のための組成物と方法
JP2009538824A (ja) 精神疾患及び障害治療用アミリン及びアミリンアゴニスト
Clark Recombinant insulin-like growth factor-1 as a therapy for IGF-1 deficiency in renal failure
Lyle et al. Human growth hormone and anti-aging
Chertman et al. Growth hormone in aging
Stonebrook et al. Growth in children with end-stage kidney disease
US20020156019A1 (en) Method of optimizing growth hormone replacement
JP2007519669A (ja) 脂肪異栄養症を治療するための方法及び組成物
Chernausek Treatment of insulin-like growth factor deficiency with IGF-I: studies in humans
Carroll et al. Growth hormone therapy may benefit protein metabolism in mitochondrial encephalomyopathy
Petriczko et al. Growth, IGF-1 and IGFBP-3 Responses to Oral LUM-201 in OraGrowtH210 and OraGrowtH212 Trials in Pediatric Growth Hormone Deficiency (PGHD) over 12 to 24 Months on Treatment
Dooley et al. Human mecasermin: a review of its use in amyotrophic lateral sclerosis
Rao Laron syndrome–A perspective on diagnosis and management in India